GILEAD SCIENCES SL

Assembly Biosciences has dosed the first participant in the Phase 1b portion of its clinical trial evaluating ABI-1179, a long-acting herpes simplex virus helicase-primase inhibitor for recurrent genital herpes.

The FDA has approved 84 drugs in 2025 so far, marking the second-highest total for this period despite major organizational changes including 3,500 staff layoffs.

Assembly Biosciences reported positive Phase 1b results for ABI-4334, a next-generation capsid assembly modulator, showing potent antiviral activity against chronic hepatitis B virus infection.

The US FDA has approved lenacapavir, a new injectable HIV prevention drug offering 99.9% protection against HIV infection.

BioNTech will lay off 63 employees and wind down cell therapy manufacturing at its Gaithersburg, Maryland facility by the end of 2025 following disappointing Phase 1 trial results.

A new comprehensive report analyzes 943 autoimmune collaboration and licensing deals from 2016-2025, covering over 30 diseases including multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease.

The FDA has placed a clinical hold on five Gilead HIV trials involving weekly combination therapy GS-1720 and GS-4182 after safety signals showed decreased CD4+ T-cell and lymphocyte counts in some patients.

Lenacapavir, a novel capsid inhibitor, demonstrated 100% effectiveness in preventing HIV transmission in the PURPOSE clinical trials, surpassing existing PrEP options.

Protara Therapeutics has appointed William Conkling as Chief Commercial Officer, bringing over two decades of experience in developing and commercializing cancer and rare disease therapeutics.

Gilead Sciences' dual-target CAR-T therapy shrank tumors in 62% of patients with recurrent glioblastoma, a rare achievement for this fatal brain cancer.